President Biden and leaders of the G-7 group of nations will endorse a global minimum corporate tax rate of at least 15% on Friday, a policy that could ultimately drive business investment away from the U.S.
ASIA: Didi Chuxing, China's biggest ride-hailing firm, on Thursday, made public the filing for its long-anticipated U.S. stock market listing, setting the stage
New disclosures of U.S. taxpayers' confidential information are motivated by Democratic Party politics and the goal of raising taxes, say taxpayer advocates.
Breaking News, Latest News and Current News from OANN.com. Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.
FDA is fighting back against Alzheimer’s
By David Williams - Contributing columnist
Alzheimer’s Disease inflicts a truly terrible toll on people. Today, roughly 6 million Americans and their families are coping with the confusion and memory loss brought on by this irreversible illness. The number of sufferers in the U.S. is expected to swell to around 14 million by the middle of the century.
Fortunately, there is hope on the horizon for victims of this devastating disease. The Food and Drug Administration (FDA) has just approved the medication aducanumab (created by Biogen), which may slow the progression of Alzheimer’s. The medication’s approval is a far greater achievement than the treatment of any one disease. With aducanumab now approved, the FDA is showing that it is willing to offer sufferers of debilitating diseases a chance to have a better future. The approval of this drug is a good sign that the FDA may be willing to put people, not bureaucracy, first.